MedPath

Amphetamine

Generic Name
Amphetamine
Brand Names
Adderall, Adzenys, Dyanavel, Evekeo, Mydayis
Drug Type
Small Molecule
Chemical Formula
C9H13N
CAS Number
300-62-9
Unique Ingredient Identifier
CK833KGX7E
Background

Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935. Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers. The first product of Smith, Kline and French was approved by the FDA on 1976.

During World War II, amphetamine was used to promote wakefulness in the soldiers. This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit abuse.

Indication

Amphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.

ADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.

On the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.

Amphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.

Associated Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Chronic Pain, Depression, Narcolepsy, Obesity
Associated Therapies
-

Caffeine and Cocaine

Phase 1
Completed
Conditions
Cocaine Dependence
Interventions
First Posted Date
2008-08-13
Last Posted Date
2017-03-22
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
23
Registration Number
NCT00733993
Locations
🇺🇸

The University of Texas Health Science Center, Houston, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath